CNTX

MKT CAP:$210M

Context Therapeutics Inc.

Market Cap

$210M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.29+$0.74 (+47.46%)

Apr 24, 2026

Company Details

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective...

CEO

Martin A. Lehr

IPO Date

Oct 20, 2021

Website

www.contexttherapeutics.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$36M

EPS (Diluted)

-$0.38

Free Cash Flow

-$26M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 6, 2026

PENDING

FY 2025

Mar 23, 2026

$0EPS -$0.38

Q4 2025

Mar 23, 2026

$0EPS -$0.14

Q3 2025

Nov 5, 2025

$0EPS -$0.10

Q2 2025

Aug 6, 2025

$0EPS -$0.09

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$3M
Q2 22	$0	$0	-$4M
Q3 22	$0	$0	-$4M
Q4 22	$0	$0	-$4M
Q1 23	$0	$0	-$7M
Q2 23	$0	$0	-$5M
Q3 23	$0	$0	-$6M
Q4 23	$0	$0	-$7M
Q1 24	$0	$0	-$4M
Q2 24	$0	$0	-$3M
Q3 24	$0	$0	-$19M
Q4 24	$0	$0	-$4M
Q1 25	$0	$0	-$6M
Q2 25	$0	$0	-$10M
Q3 25	$0	-$4.1K	-$11M
Q4 25	$0	-$32.3K	-$14M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$4M	-$4M
Q2 22	-$3M	-$3M
Q3 22	-$3M	-$3M
Q4 22	-$4M	-$4M
Q1 23	-$6M	-$6M
Q2 23	-$5M	-$5M
Q3 23	-$3M	-$3M
Q4 23	-$7M	-$7M
Q1 24	-$4M	-$4M
Q2 24	-$3M	-$3M
Q3 24	-$2M	-$2M
Q4 24	-$5M	-$5M
Q1 25	-$5M	-$5M
Q2 25	-$6M	-$6M
Q3 25	-$7M	-$7M
Q4 25	-$9M	-$9M

Capital Expenditures

Quarter	CapEx
Q1 22	$35.0K
Q2 22	$1.8K
Q3 22	$500.0K
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$4
Q3 24	$7.3K
Q4 24	$0
Q1 25	$33.9K
Q2 25	$0
Q3 25	$0
Q4 25	$5

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+309.7%
Q2 22	—	-20.3%
Q3 22	—	+158.2%
Q4 22	—	+25.6%
Q1 23	—	+93.6%
Q2 23	—	+32.1%
Q3 23	—	+52.7%
Q4 23	—	+78.6%
Q1 24	—	-42.6%
Q2 24	—	-41.6%
Q3 24	—	+202.6%
Q4 24	—	-37.8%
Q1 25	—	+44.6%
Q2 25	—	+216.0%
Q3 25	—	-43.3%
Q4 25	—	+220.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$215.0K	—
Q2 22	$241.3K	—
Q3 22	$276.5K	—
Q4 22	$243.6K	—
Q1 23	$282.8K	—
Q2 23	$283.1K	—
Q3 23	$254.9K	—
Q4 23	$256.1K	—
Q1 24	$240.0K	—
Q2 24	$157.0K	—
Q3 24	$213.0K	—
Q4 24	$231.8K	—
Q1 25	$293.7K	—
Q2 25	$389.1K	—
Q3 25	$323.1K	—
Q4 25	$325.2K	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$1M	$2M	—
Q2 22	$2M	$2M	—
Q3 22	$2M	$2M	—
Q4 22	$2M	$2M	—
Q1 23	$5M	$2M	—
Q2 23	$3M	$2M	—
Q3 23	$4M	$2M	—
Q4 23	$5M	$2M	—
Q1 24	$2M	$2M	—
Q2 24	$1M	$2M	—
Q3 24	$17M	$2M	—
Q4 24	$3M	$2M	—
Q1 25	$3M	$2M	—
Q2 25	$8M	$2M	—
Q3 25	$9M	$2M	—
Q4 25	$12M	—	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$46M	$0	$46M
Q2 22	$43M	$0	$43M
Q3 22	$39M	$0	$39M
Q4 22	$35M	$0	$35M
Q1 23	$30M	$0	$30M
Q2 23	$25M	$0	$25M
Q3 23	$22M	$0	$22M
Q4 23	$14M	$0	$14M
Q1 24	$10M	$0	$10M
Q2 24	$102M	$0	$102M
Q3 24	$85M	$0	$85M
Q4 24	$94M	$0	$94M
Q1 25	$89M	$0	$89M
Q2 25	$84M	$0	$84M
Q3 25	$77M	$0	$77M
Q4 25	$66M	$0	$66M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	16M	+56.4%	+56.4%
Q2 22	16M	0.0%	+132.2%
Q3 22	16M	0.0%	+4321.9%
Q4 22	16M	0.0%	+56.4%
Q1 23	16M	0.0%	0.0%
Q2 23	16M	0.0%	0.0%
Q3 23	16M	0.0%	0.0%
Q4 23	16M	0.0%	0.0%
Q1 24	16M	0.0%	0.0%
Q2 24	55M	+244.2%	+244.2%
Q3 24	80M	+46.4%	+404.1%
Q4 24	58M	-27.4%	+265.9%
Q1 25	95M	+62.9%	+496.2%
Q2 25	95M	-0.0%	+73.2%
Q3 25	95M	-0.0%	+18.3%
Q4 25	92M	-3.5%	+57.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	7
Q2 22	$0	7
Q3 22	$0	7
Q4 22	$0	9
Q1 23	$0	9
Q2 23	$0	9
Q3 23	$0	9
Q4 23	$0	5
Q1 24	$0	5
Q2 24	$0	5
Q3 24	$0	5
Q4 24	$0	12
Q1 25	$0	12
Q2 25	$0	12
Q3 25	$0	12
Q4 25	$0	200K

Revenue / Employee